Patent ID: 7851486

Claim:
A method of treating a human subject to reduce risk of myocardial infarction (MI) comprising: screening nucleic acid of a human subject to determine whether the nucleic acid comprises a 5-lipoxygenase activating protein (FLAP) (SEQ ID NO: 1) genotype or haplotype that correlates with an increased risk for MI, wherein the FLAP genotype or haplotype comprises at least one polymorphism selected from the group consisting of the polymorphisms set out in Table 5 or 7, selecting a human subject comprising the FLAP genotype or haplotype that correlates with an increased risk for MI, and administering to the human subject a composition comprising a therapeutically effective amount of an MI therapeutic agent that inhibits leukotriene synthesis in vivo, wherein the MI therapeutic agent is a compound represented by the formula: or pharmaceutically acceptable salt thereof, wherein R 1 represents a group of the formula: R 2 and R 3 are identical or different and represent hydrogen, lower alkyl, phenyl, benzyl or a group of the formula: R 4 represents hydrogen, lower alkyl, phenyl or benzyl, which can optionally be substituted by hydroxyl, carboxyl, lower alkoxycarbonyl, lower alkylthio, heteroaryl or carbamoyl, R 5 represents hydrogen, lower alkyl, phenyl or benzyl, R 6 represents a group of the formula —COR 5 or —CO 2 R 5 , R 7 represents hydrogen, lower alkyl or phenyl, Y represents a group of the formula: wherein R 8 represents hydrogen, lower alkyl or phenyl and n denotes a number of 0 to 5, Z represents norbornyl, or represents a group of the formula: wherein R 9 and R 10 are identical or different and denote hydrogen, lower alkyl or phenyl, or R 9 and R 10 can together form a saturated carbocyclic ring having up to 6 carbon atoms and m denotes a number from 1 to 6, and A and B are identical or different and denote hydrogen, lower alkyl or halogen, or a pharmaceutically acceptable salt thereof.